The deal involves Eli Lilly, which makes Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy. The drugs, known as GLP-1 medications, now cost as much as $1350 a month. Under the ...

Oral GLP-1 weight loss pills could replace injections by March 2026 at $150 monthly, Medicare chief Dr. Mehmet Oz predicted in a FOX Business appearance.

Novo Nordisk NVO is a dominant player in the cardiometabolic space, which markets its blockbuster semaglutide-based (GLP-1) ...

Economist Emily Oster joins Michael Smerconish to discuss the growing debate over whether Medicare and Medicaid should cover ...

People taking GLP-1 meds could see costs drop in 2026, thanks to a new federal deal with Eli Lilly and Novo Nordisk, the ...

Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new ...

If Trump decides to go ahead and pursue a piece of Novo Nordisk, he would be under more public pressure to successfully lower ...

Novo Nordisk A/S & Eli Lilly and Company cut prices for top diabetes drugs, boosting accessibility and potential revenue.

The nationwide weight-loss goal Oz mentioned Thursday would be significantly more realistic if he intended to say 135 million ...

At a White House event Thursday, President Trump announced deals with drug makers Novo Nordisk and Eli Lilly to offer their ...

The list prices of obesity drugs Wegovy and Zepbound are over $1,000, but that’s not necessarily what you pay.

In the Oval Office today, the president announced that he had secured a deal to dramatically slash the price of obesity drugs ...